Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

• Status: Terminated
• Trial end date: 2017-05-09
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

• Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma

• Documentation of previous treatment including conventional chemotherapy and/or radiation therapy as clinically appropriate

• Ages 2 to 30 years of age

• Negative serum pregnancy test if applicable

• Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of less than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate aminotransferase (AST) must be less than twice the upper limit of normal

Exclusion Criteria:

• Unsuitable candidate for autologous transplantation due to comorbidities or intractable psychosocial issues

• Pregnancy

• Breast-feeding women